Brent Saunders

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Retrieved on: 
Wednesday, February 15, 2023
General Health, Health, Optical, Bausch, Bausch & Lomb, Actavis, Safety, NYSE, Patient, Brent Saunders, Allergan, Bausch Health, Schering-Plough, History, Lead, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023.
  • Additionally, effective upon Mr. Saunders’ appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.
  • To facilitate an orderly transition, Mr. Saunders will join Bausch + Lomb on Feb. 16, 2023, in an advisory capacity, where he will work closely with Mr. Papa.
  • Mr. Saunders will return to Bausch + Lomb after having served at the Company as CEO from 2010 to 2013.

The Beauty Health Company Announces CEO Transition

Retrieved on: 
Tuesday, November 9, 2021
Other Retail, Fitness & Nutrition, Specialty, Other Health, Health, Cosmetics, Pharmaceutical, General Health, Retail, The Business Council, Schering-Plough, Â, Private Securities Litigation Reform Act, AbbVie, Ecosystem, Director, Partner, SKIN, Leadership, Investor relations, Merck, NASDAQ, LLP, CEO, Telecommunication, Senior, Growth, Actavis, PricewaterhouseCoopers, Instagram, COVID-19, Beauty, Board, Acquisition, Company, Awareness, Disclosure, LinkedIn, Cisco Systems, Solution, Compliance, Coventry Health Care, Skin care, Vaccine, Merck & Co., Management, Risk management, Brent Saunders, The Beauty Health Company, BRENT SAUNDERS, THE BEAUTY HEALTH COMPANY

The Beauty Health Company ("BeautyHealth" or the "Company"; NASDAQ:SKIN), a global category-creator in beauty health leading the charge with its flagship brand HydraFacialTM, today announced that, following its third quarter record performance, Clint Carnell will be transitioning out of his role as Chief Executive Officer of the Company.

Key Points: 
  • The Beauty Health Company ("BeautyHealth" or the "Company"; NASDAQ:SKIN), a global category-creator in beauty health leading the charge with its flagship brand HydraFacialTM, today announced that, following its third quarter record performance, Clint Carnell will be transitioning out of his role as Chief Executive Officer of the Company.
  • We are building an enduring and premier company in the category of beauty health.
  • Brent Saunders has served as Executive Chairman of The Beauty Health Company since its inception in May 2021.
  • Important factors, among others, that may affect actual results or outcomes include the expected timing of changes to management and the idenficiation of a new permanent CEO, The Beauty Health Companys ability to manage growth; The Beauty Health Companys ability to execute its business plan, including with respect to potential acquisitions; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors; and the impact of the continuing COVID-19 pandemic on the Companys business.